Literature DB >> 1889178

Comparison of agar versus broth dilution techniques for determining antibiotic susceptibilities of Ureaplasma urealyticum.

K B Waites1, T A Figarola, T Schmid, D M Crabb, L B Duffy, J W Simecka.   

Abstract

We determined minimal inhibitory concentrations (MIC) for tetracycline and erythromycin for 72 clinical isolates using broth and agar dilution methods. Erythromycin MIC ranges were less than 0.125-8 micrograms/ml and 1-64 micrograms/ml in broth and agar, respectively. The erythromycin MIC50 and MIC90 as determined by broth were two dilutions (fourfold) lower than those for agar. Tetracycline MIC ranges in broth and agar were less than 0.125-greater than 64 and 0.25-greater than 64 micrograms/ml, respectively. The tetracycline broth MIC50 was one dilution lower than that for agar. The tetracycline broth MIC90 was 64 micrograms/ml and that for agar was greater than 64 micrograms/ml. Of the strains tested, 98.6% using broth were susceptible or moderately susceptible to erythromycin as compared with 75% using agar, representing a significant difference (p less than 0.001). For tetracycline, 80.6% of strains were susceptible or moderately susceptible using broth and 73.6% using agar. MICs were determined by agar dilution after 72 and 96 hr of incubation in 32 strains. There was an increase in the erythromycin MIC by one dilution in 16 strains and two dilutions in one strain with the longer incubation. The tetracycline MIC increased by one dilution in nine strains between readings. Broth MICs were reproducible with one dilution for both drugs in 10 of 12 strains tested twice. Agar MICs were reproducible within a maximum of two dilutions (fourfold). Different interpretations of susceptibility versus resistance may be made depending on which assay is utilized, thus influencing conclusions regarding spectrum of activity of investigational drugs as well as treatment options. The technique employed should always be considered whenever apparently differing drug susceptibility patterns are reported.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889178     DOI: 10.1016/0732-8893(91)90041-d

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

2.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Role of biofilm formation in Ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates.

Authors:  Katherine Pandelidis; Amanda McCarthy; Kirsty L Chesko; Rose M Viscardi
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

5.  Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.

Authors:  Shasha Rao; Clive A Prestidge; Lynn Miesel; Deb Sweeney; Dean L Shinabarger; Ramiz A Boulos
Journal:  J Antibiot (Tokyo)       Date:  2016-05-18       Impact factor: 2.649

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.